Aprea Therapeutics Inc(APRE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 7:49 PM ET (Korea 11/4 09:49)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.08 | Insider Own | 8.98% | Shs Outstand | 12.4M | Perf Week | 0.39% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -11.02% | Insider Trans | - | Shs Float | 11.5M | Perf Month | -23.77% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -0.07 | Inst Own | 39.02% | Short Float | 5.42% | Perf Quarter | -17.07% |
| Income | -0.01B | P/S | 648.21 | EPS this Y | 83.55% | Inst Trans | 3.35% | Short Ratio | 2.02 | Perf Half Y | -38.92% |
| Sales | 0.00B | P/B | 0.17 | EPS next 5Y | 43.58% | ROA | -41.3% | Short Interest | 0.62M | Perf YTD | -39.62% |
| Book/sh | 3.1 | P/C | 0.16 | EPS past 3/5Y | 88.77% 47.99% | ROE | -46.15% | 52W High | -65.44% ($1.49) | Perf Year | -63.21% |
| Cash/sh | 3.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -31.4% | 52W Low | 25.61% ($0.41) | Perf 3Y | -87.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 53.42% | Gross Margin | -324.92% | Volatility(W/M) | 12.37% 11.46% | Perf 5Y | -99.51% |
| Dividend TTM | - | EV/Sales | -3401.79 | Sales Y/Y TTM | -99.38% | Oper. Margin | -255025.52% | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.55 | EPS Q/Q | 87.4% | Profit Margin | -237362.8% | RSI (14) | 41.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.55 | Sales Q/Q | -100% | SMA20 | -5.87% ($0.54) | Beta | 1.72 | Target Price | $3.3 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/12 | SMA50 | -25.1% ($0.68) | Rel Volume | 0.21 | Prev Close | $0.49 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 60.56% -100% | SMA200 | -31.25% ($0.74) | Avg Volume(3M) | 0.31M | Price | $0.51 |
| IPO | 2019/10/3 | Option/Short | No/Yes | Trades | 92 | Volume | 63,811 | Change | 4.89% |
🧬 This is a clinical-stage biotech developing targeted oncology drugs that treat solid tumors by exploiting cancer cells' DNA damage response (DDR) mechanisms. It is a tiny Nasdaq-listed company with two key pipeline assets: an oral WEE1 inhibitor called APR-1051 and a macrocyclic ATR inhibitor called ATRN-119.
Over the past 1 year, on the lower side
66% below its 1-year high.
Traded less than usual. That is 21% of its average volume.
APRE has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +83.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $64,821. Peers typically go for $931.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.5%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 39.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #533 of 597 in the industry
Based on market cap of $6M.
XCUR#530 Exicure Inc $7M PER - 
FBLG#531 FibroBiologics Inc $7M PER - 
EVGN#532 Evogene Ltd $7M PER - APRE#533 Aprea Therapeutics Inc $6M PER - 
AIM#534 AIM ImmunoTech Inc $6M PER - 
FAQ
What kind of company is APRE?
APRE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of APRE?
The market cap of APRE is approximately $6M, ranking 5,552 within its sector.
What is the 52-week high and low for APRE?
APRE has recorded a 52-week high of $1.49 and a low of $0.41.
